Company news

Puma Biotechnology Inc news in 2023

Puma Biotechnology Inc's news releases, calls and decks from 2023, newest first.

View company

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

December 10, 2023

Puma Biotechnology Reports Third Quarter 2023 Financial Results

November 1, 2023

Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

October 13, 2023

Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

August 7, 2023

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

June 3, 2023

Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology

March 13, 2023

Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results

March 1, 2023

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results

February 15, 2023

Puma Biotechnology Releases Updated Corporate Presentation

January 8, 2023

Calls in 2023

Decks in 2023